Lynparza improved median time patients lived without disease progression to over four and half years in BRCA-mutated advanced ovarian cancer vs. just over one year with placebo

Pressmeddelanden   •   Sep 18, 2020 09:17 CEST

AstraZeneca and MSD’s Lynparza (olaparib) demonstrated a long-term progression-free survival (PFS) benefit versus placebo as a 1st-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated (BRCAm) ovarian cancer who had a complete or partial response following platinum-based chemotherapy.

Imfinzi demonstrated unprecedented survival in unresectable, Stage III non-small cell lung cancer with an estimated 50% of patients surviving four years

Pressmeddelanden   •   Sep 18, 2020 09:16 CEST

Updated results from the PACIFIC Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) demonstrated a sustained, clinically meaningful overall survival (OS) and progression-free survival (PFS) benefit in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who had not progressed following concurrent chemoradiation therapy (CRT).

COVID-19 vaccine AZD1222 clinical trials resumed in the UK

Pressmeddelanden   •   Sep 12, 2020 15:22 CEST

​Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.

AstraZeneca to list US ADR equity and all US debt securities on Nasdaq

Pressmeddelanden   •   Sep 10, 2020 08:03 CEST

AstraZeneca today announced that it will be transferring the listing of its American Depositary Receipts (ADRs) and its US listed debt securities from the New York Stock Exchange (NYSE) to the Nasdaq Global Select Market (Nasdaq) and Nasdaq Bond Exchange respectively. The transfers will be effective after market close on Thursday 24 September 2020.

Fasenra met both co-primary endpoints of reduced nasal polyp size and blockage in the OSTRO Phase III trial for patients with chronic rhinosinusitis with nasal polyps

Pressmeddelanden   •   Sep 10, 2020 08:01 CEST

​High-level results from the OSTRO Phase III trial showed AstraZeneca’s Fasenra (benralizumab) compared with placebo demonstrated a statistically significant improvement in the size of nasal polyps and in nasal blockage in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Statement on AstraZeneca Oxford SARS-CoV-2 vaccine, AZD1222, COVID-19 vaccine trials temporary pause

Pressmeddelanden   •   Sep 09, 2020 15:20 CEST

​As part of the ongoing randomised, controlled clinical trials of the AstraZeneca Oxford coronavirus vaccine, AZD1222, a standard review process has been triggered, leading to the voluntary pause of vaccination across all trials to allow an independent committee to review the safety data of a single event of an unexplained illness that occurred in the UK Phase III trial.

Biopharma leaders unite to stand with science

Pressmeddelanden   •   Sep 08, 2020 12:31 CEST

​Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines

AstraZeneca aims to transform cancer treatment and advance clinical practice with data presented at ESMO 2020

Pressmeddelanden   •   Sep 08, 2020 08:02 CEST

AstraZeneca will present new developments in pursuit of its ambition to eliminate cancer as a cause of death at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, 19 to 21 September.

New analyses from Breztri Aerosphere Phase III ETHOS trial to be presented at the European Respiratory Society International Congress 2020

Pressmeddelanden   •   Sep 07, 2020 08:08 CEST

​A post-hoc analysis of the Phase III ETHOS trial showed a consistent benefit of Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) in reducing the rate of moderate or severe chronic obstructive pulmonary disease (COPD) exacerbations across all seasons compared with Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in patients with moderate to very severe disease.

Imfinzi approved in the EU for the treatment of extensive-stage small cell lung cancer

Pressmeddelanden   •   Sep 01, 2020 08:06 CEST

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union for the 1st-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin.

Kontaktpersoner 4 kontaktpersoner

  • Presskontakt
  • Presschef, AstraZeneca AB och Norden-Baltikum
  • chvbrieustvhincpa.uwmabolmupbenrrgvshaurgeasrsextrtaanabd@uuasyetrffazcoenfhecwca.ctcovgmkc
  • +46 8 552 531 06
  • +46 72 855 93 29

  • Presskontakt
  • Kommunikationsdirektör AstraZeneca Norden, Baltikum och ordförande Leif Johanssons kontor
  • janacohhb.mrlutlndtm@aristnzrabyzepunetqcaie.cdiomxj
  • 08 553 260 20 Mobil: 072 560 21 57

Om AstraZeneca

Om AstraZeneca

AstraZeneca är ett globalt, innovationsdrivet bioläkemedelsföretag med fokus på forskning, utveckling och marknadsföring av receptbelagda läkemedel, primärt för behandling av sjukdomar inom tre huvudsakliga terapiområden: cancer, kardiovaskulära sjukdomar, njursjukdomar och metabola sjukdomar och sjukdomar i andningsvägarna. AstraZeneca bedriver verksamhet i över 100 länder och dess innovativa läkemedel används av miljontals patienter över hela världen. Mer information finns på: www.astrazeneca.com och www.astrazeneca.se